GNI Group Ltd. (TYO:2160)
Japan · Delayed Price · Currency is JPY | Market Cap | 227.47B +69.0% |
| Revenue (ttm) | 26.53B +9.9% |
| Net Income | -5.32B |
| EPS | -96.36 |
| Shares Out | 65.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,996,900 |
| Open | 3,445.00 |
| Previous Close | 3,455.00 |
| Day's Range | 3,425.00 - 3,640.00 |
| 52-Week Range | 2,112.00 - 3,740.00 |
| Beta | 1.19 |
| Analysts | Strong Buy |
| Price Target | 4,400.00 (+21.05%) |
| Earnings Date | Nov 13, 2026 |
About GNI Group
GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of pharmaceuticals and biomaterials in Japan, China, and the United States. It operates in two segments, Pharmaceutical Business and Medical Equipment Business. The company offers ETUARY for the treatment of idiopathic pulmonary fibrosis; H-GENIN Crush-Mix for the treatment of bone defects; AltiPly for the treatment of acute and chronic wounds; and orthobiologics products. It also develops ETUARY which is in Phase III clinical trial for... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for 2160 stock is "Strong Buy." The 12-month stock price target is ¥4,400, which is an increase of 21.05% from the latest price.
News
GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company
Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas Transaction Establishes a Large-Scale Pharmaceutical Platfor...